| Name | Title | Contact Details |
|---|
LandsteinerScientific is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Attune Pharmaceuticals is a private biotechnology company focused on discovering and developing novel orally-administered small-molecule therapeutics for the treatment of rare diseases.
At SI Group, we create smart chemistry that solves global challenges and makes great things possible. We create smart chemistry that solves global challenges and makes great things possible. SI Group is a performance additives and intermediates business. We offer a broad array of products that feed into diverse applications including pharmaceuticals; plastics; oil and gas; and tires, among many others. We create solutions that provide formulators and manufacturers with the ability to increase efficacy, efficiency, productivity, and purity in countless industrial and consumer goods. Our company unites us. So do our values and the approach that we bring into the workplace each day.
PAR Pharmaceuticals is a Woodcliff Lake, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Heron Therapeutics is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by extending the duration of action. The Company's lead product, SUSTOL™ (formerly APF530), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. Heron Therapeutics received a Complete Response Letter to its SUSTOL New Drug Application (NDA) and is targeting a resubmission of the NDA to the U.S. Food and Drug Administration during the fourth quarter of 2014. Heron Therapeutics' core Biochronomer technology, on which SUSTOL and its other products are based, consists of bioerodible polymers designed to release drugs over a defined period of time. The Company has completed over 100 in vivo and in vitro studies demonstrating that its Biochronomer technology is potentially applicable to a range of therapeutic areas, including prevention of nausea and vomiting, pain management, control of inflammation and treatment of ophthalmic diseases. Heron Therapeutics has also completed comprehensive animal and human toxicology studies that have established that its Biochronomer polymers are generally well tolerated. Furthermore, the Company's Biochronomer technology can be designed to deliver drugs over periods varying from days to several months. In addition to its lead drug candidate SUSTOL, Heron Therapeutics has a pipeline of other product candidates that use the Biochronomer technology.